Previous close | 21.20 |
Open | 22.69 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 22.69 - 22.69 |
52-week range | 17.45 - 32.05 |
Volume | |
Avg. volume | 88 |
Market cap | 1.965B |
Beta (5Y monthly) | 1.33 |
PE ratio (TTM) | 12.33 |
EPS (TTM) | 1.84 |
Earnings date | 21 Aug 2024 - 26 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
COPENHAGEN, Denmark, May 22, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 187,020 as a consequence of employees’ exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. A total of 18,702 new shares were subscribed for in cash at DKK 146.60 per share of nominally DKK 10. The total proceeds to Bavarian Nordic A/S from the capital incr
COPENHAGEN, Denmark, May 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on May 8, 2024, has now been terminated, as the intended number of shares under the program has been repurchased. The program was executed in accordance with the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and supplementing Regulation (EU) 2016/1052 of 8 March 2016, which toge
COPENHAGEN, Denmark, May 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that Laurence de Moerlooze will leave her position as Executive Vice President and Chief Medical Officer in the Company to pursue new opportunities. She will continue to support Bavarian Nordic until the end of May 2024. The Company will initiate a search process to identify the next Chief Medical Officer. Paul Chaplin, President & CEO of Bavarian Nordic, said: “On behalf of everyone at Bavarian Nordic, I want to